David Edwards received his undergraduate pharmacy degree from the University of Toronto in 1978 and completed a residency in hospital pharmacy at Sunnybrook Medical Centre. He graduated from the PharmD program at the State University of New York at Buffalo and joined the Department of Pharmaceutics at Buffalo for post-doctoral training in pharmacokinetics.
Dr. Waite’s research program examines the development and assessment of curricula to produce pharmacists prepared to provide medication management in an evolving healthcare landscape, as well as explores the impact of novel pharmacist interventions and pharmacist scope of practice changes on medication management and health outcomes.
Dr. Alsabbagh’s research interests are in pharmacoepidemiology of chronic medications, in particular cardiovascular medications. His research includes employing administrative databases to examine the utilization and health-outcomes of chronic medications. Dr. Alsabbagh is also pursuing research investigating the comparative effectiveness and safety of chronic medications.
Dr. Michael Beazely’s lab research focuses on understanding how growth factor receptors and G protein-coupled receptors modulate ion channels and neuronal cell function. His clinical and education research is focused on the role of health professionals in reducing harms associated with problematic substance use.
Dr. Blay’s main research focus is in understanding the tumour microenvironment of solid cancers, particularly colorectal carcinoma.
His laboratory focuses on mechanisms that lead to the spread of colorectal cancer, and ways to interfere with that dissemination of disease, or metastasis.
Dr. Chang is a clinical pharmacist specializing in geriatric pharmacotherapy. Her research interests include caring for vulnerable older adults in primary care settings, particularly older adults in rural areas, for conditions such as chronic pain and dementia, and the role of pharmacists in care provision.
Dr. Edginton’s research focuses on building virtual organisms to study the pharmacokinetics of drugs and environmental contaminants. Using pharmacokinetic (PBPK) models to provide a mechanistic means of understanding how changes in physiology can affect the absorption, metabolism and excretion of a chemical.
Dr. Foldvari's research focuses on the development of intelligent delivery systems and biomolecular devices with the goal of developing new, non-invasive technologies to deliver and target therapeutic agents into the body and to diseased tissues, as well as investigating the fundamental properties of these delivery technologies and the cells they target.
Dr. Grindrod's research focuses on using digital technologies to improve how we manage medications. She is currently examining how patients, physicians and pharmacists share medication information. She is also interested in how digital technologies can be used to change clinician practice.
The HoResearchGroup is interested in the development and characterization of innovative drug delivery strategies including nanomedicines, medical devices and biomaterials for the treatment and prevention of HIV/AIDS, cancer, and chronic wound healing.
Dr. Houle's research interests are on the role of the pharmacist as a patient care provider, especially related to expanded scope activities such as prescribing and administering injections, and the resulting clinical and economic outcomes of these activities.
Dr. Joseph’s research is focused on ascertaining how the β-cell senses glucose and on searching for ways to reduce the number of islets required for islet transplantation. These two themes are connected in that the first theme provides novel targets to enhance islet function in the second theme.
Dr. Maxwell’s primary research interests are in the areas of Pharmacoepidemiology and Aging with a particular focus on Alzheimer’s disease and vascular dementia, depression and health services and outcomes research.
She is also involved in national and international research examining the health and quality of care needs of older residents within Assisted Living and Long Term Care settings.
Dr. Tom McFarlane teaches oncology, internal medicine, and immunology topics to the undergraduate students at the School of Pharmacy. He has a particular interest in GI, lung, and prostate cancers, and conducts practice based research in these settings which includes exploring ways of improving supportive care regimens for patients and the impact of supportive care on overall outcomes.
Dr. Nagge’s clinical and research interests include cardiovascular risk reduction, anticoagulation therapy, translating evidence into practice, and shared decision making.
Dr. Nekkar Rao specializes in medicinal and bioorganic chemistry; exploring rational drug design aided by molecular modelling techniques and small molecule synthetic organic/medicinal chemistry.
Dr. Patel’s research interests are in pharmacotherapeutic management of neurological conditions, in particular epilepsy, dementia and chronic pain.
Her current research interests include the assessment, classification and management of drug related problems in persons presenting with cognitive impairment as well as the frail elderly in primary care settings.
Dr. Richard completed her undergraduate degree in pharmacy at Dalhousie University, and has experience in community pharmacy. She completed her PhD in Pharmacology at Dalhousie University, and then studied vitamin D’s anti-cancer activity during a post-doctoral research fellowship at the University of Guelph.
Dr. Slavcev’s interests are in genetics, molecular biology, virology and technology transfer.
Dr. Wong’s research focuses on system-level policy modeling, infectious diseases modeling, health services and outcomes research, particularly in hepatitis B and C. His health services and outcomes research interests include quality of life research, costing and return on investment.
Dr. Wettig's research focuses on the design, synthesis and characterization of novel surfactants with an eye toward their application in drug delivery.
Dr. Gamble is a pharmacist and epidemiologist who leads a research program in drug safety and effectiveness. His team focuses on understanding the real-world use and effects of diabetes therapies. Moreover, Dr. Gamble’s lab is interested in exploring methods to communicate drug information to facilitate evidence informed decision making for patients, health provider, and policy-makers.